Cemiplimab, a human monoclonal antibody to PD-1, in patients with advanced cutaneous squamous cell carcinoma (CSCC): Clinical experience from the phase 1 and phase 2 studies
Michael R Migden, Alexander Guminski, Karl D Lewis, Nikhil I Khushalani, Kyriakos P Papadopoulos, Yamini Patel, Michael Andria, Matthew G Fury, Danny Rischin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2019
Supported by Regeneron Pharmaceutical Inc. and Sanofi. Medical writing support under the direction of the authors was provided by Emmanuel Ogunnowo, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc.